Dr Mackenzie brings to CMPT a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics Ltd, Oxford Biomedica plc (an LSE listed company), Avidex Ltd (now Immunocore) and
Before being appointed as the CEO, Dr Mackenzie was the SVP for business development and corporate strategy at Medigene and CEO of Roji Ltd (London).
Achim Kaufhold, chairman of CMPT, said: “Now is a pivotal time for CMPT as we move into advanced clinical development for our lead product and we are delighted to welcome Dr Mackenzie as CEO.”
Dr Mackenzie said: “I am delighted to have been chosen for this role. With a lead compound that has Over-The-Counter (OTC) potential as a treatment for the common cold we hope to be ready for the market shortly after we have completed clinical trials over the next two years.”